New drug hope for Kids' lung damage after transplant
NCT ID NCT04908735
First seen Jan 08, 2026 · Last updated May 14, 2026 · Updated 20 times
Summary
This study tested the drug ruxolitinib for children and adults who developed early lung problems after a stem cell transplant. Lung issues like bronchiolitis obliterans (BO) can be serious and are often found too late. The goal was to see if adding ruxolitinib to standard treatment could reverse lung damage and prevent long-term breathing problems. The study was stopped early after enrolling only 7 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.